Longhorn Advances a Scalable Universal Flu Vaccine
April 14th 2025Jeff Fischer, MBA, discusses promising preclinical data on a cross-species, cross-strain influenza candidate with pandemic potential at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases.
Read More
Top 5 HIV Stories from CROI 2025: New Treatments, HIV Remission Insights, and More
March 21st 2025Studies presented included once-yearly lenacapavir formulations for PrEP, bictegravir outperforming darunavir in advanced HIV, Immunocore's IMC-M113V showing viral control and reservoir reduction, and more.
Read More
ViiV Healthcare Presents Potential Long-Acting HIV Therapies
March 17th 2025Phase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.
Watch
Doravirine and Islatravir Combination Shown to be Noninferior to Once-Daily ART
March 12th 2025In a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.
Watch
The M&M Study: Age-Related T Cell Response in People with HIV on ART in MVA.HIVconsvX Vaccine Trial
March 10th 2025Nilu Goonetilleke, LLBHons, BScHons, presents findings from the phase 1 study, showing a 50% reduction in T cell response with age, while 85% of participants demonstrated strong immune responses.
Watch
Imdusiran for Chronic Hepatitis B Achieves Functional Cure in 50% of Patients
November 18th 2024Arbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.
Watch